| SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer. | SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer.
Phillips JB, Park SS, Lin CH, Cho J, Lim S, Aurora R, Kim JH, Angajala A, Park B, Stone JK, Wang B, Kahn AG, Lim SS, Kim JH, Ahn EE, Tan M., | 11/7/2024 |
| Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. | Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells.
Dennis M, Hurley A, Bray N, Cordero C, Ilagan J, Mertz TM, Roberts SA., Free PMC Article | 10/31/2024 |
| Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes. | Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes.
Liu X, Song Y, Cheng P, Liang B, Xing D. | 10/25/2024 |
| A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice. | A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice.
Yang H, Wang X, Blanco-Gómez A, He L, García-Sancha N, Corchado-Cobos R, Pérez-Baena MJ, Jiménez-Navas A, Wang P, Inman JL, Snijders AM, Threadgill DW, Balmain A, Chang H, Perez-Losada J, Mao JH., Free PMC Article | 09/25/2024 |
| HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. | HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS., Free PMC Article | 09/11/2024 |
| A Comparison of Immunohistochemical Expression of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 in Dental Follicles with Different Radiographic Sizes. | A Comparison of Immunohistochemical Expression of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 in Dental Follicles with Different Radiographic Sizes.
Saravani S, Nemati Rezvani H, Shahraki M, Kadeh H., Free PMC Article | 09/11/2024 |
| [Clinicopathological features of breast cancer with HER2 low expression: a real-world retrospective study]. | [Clinicopathological features of breast cancer with HER2 low expression: a real-world retrospective study].
Li KM, Wu SF, Sun MC, Zhang HX, Teng XY, Liu YY, Liang ZY, Zeng X. | 07/24/2024 |
| Exercise-induced beta2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded gammadelta T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition. | Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition.
Baker FL, Smith KA, Mylabathula PL, Zúñiga TM, Diak DM, Batatinha H, Niemiro GM, Seckeler MD, Pedlar CR, O'Connor DP, Colombo J, Katsanis E, Simpson RJ., Free PMC Article | 07/15/2024 |
| Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2. | Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2.
Yuan Y, Hao L, Huang JS, Zhao FY, Ju YH, Wang JM, Zhang T, Li BQ, Yu ZW., Free PMC Article | 07/10/2024 |
| Mitochondrial HER2 stimulates respiration and promotes tumorigenicity. | Mitochondrial HER2 stimulates respiration and promotes tumorigenicity.
Novotna E, Milosevic M, Prukova D, Magalhaes-Novais S, Dvorakova S, Dmytruk K, Gemperle J, Zudova D, Nickl T, Vrbacky M, Rosel D, Filimonenko V, Prochazka J, Brabek J, Neuzil J, Rohlenova K, Rohlena J. | 07/1/2024 |
| Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations. | Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
Kaneko S, Takasawa K, Asada K, Shiraishi K, Ikawa N, Machino H, Shinkai N, Matsuda M, Masuda M, Adachi S, Takahashi S, Kobayashi K, Kouno N, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Saloura V, Kohno T, Hamamoto R., Free PMC Article | 06/25/2024 |
| Immunohistochemical Human Epidermal Growth Factor Receptor 2 (HER2) Expression Pattern in Gastric Adenocarcinomas in a Nigerian Tertiary Hospital. | Immunohistochemical Human Epidermal Growth Factor Receptor 2 (HER2) Expression Pattern in Gastric Adenocarcinomas in a Nigerian Tertiary Hospital.
Mashor MI, Ezenkwa US, Ogun GO, Ajani MA, Ogunbiyi JO. | 06/8/2024 |
| Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer. | Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. | 05/29/2024 |
| Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma. | Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma.
Bui CM, Oren A, Balzer B, Maluf H, Medeiros F. | 05/29/2024 |
| The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma. | The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.
Estephan F, Lap CJ, Banagan J, Antonio M, Liu S, Diao G, Rozalen AZ, Rajendran R, Krasnow S, Subrahmanyam R, Nava VE, Jain M. | 04/22/2024 |
| Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review. | Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review.
Fakhrioliaei A, Tanhaei S, Pakmehr S, Noori Shakir M, Qasim MT, Hariri M, Nouhi Kararoudi A, Valilo M. | 04/17/2024 |
| Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer. | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN, Chung YS, Park E, Lee ST, Lee JY., Free PMC Article | 04/16/2024 |
| Site-specific glycosylation analysis of epidermal growth factor receptor 2 (ErbB2): exploring structure and function toward therapeutic targeting. | Site-specific glycosylation analysis of epidermal growth factor receptor 2 (ErbB2): exploring structure and function toward therapeutic targeting.
Fujitani N, Uehara Y, Ariki S, Hashimoto U, Mukai J, Hasegawa Y, Takahashi M., Free PMC Article | 04/4/2024 |
| EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation. | EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Zhao R, Li J, Guo L, Xiang C, Chen S, Zhao J, Shao J, Zhu L, Ye M, Qin G, Chu T, Han Y. | 03/28/2024 |
| Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. | Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol ES, Sivakumar S, Ross JS, Cheng L. | 03/26/2024 |
| Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma. | Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.
Rong L, Zhao H, Li Y, Jin M, Lu J. | 03/25/2024 |
| Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. | Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R, Nishikawa T, Yoshida H, Mizoguchi C, Yamamoto K, Kato T, Yonemori K., Free PMC Article | 03/20/2024 |
| Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy. | Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Blas PE, Rodriguez ESR, Williams HL, Levin MK, Bell JSK, Pierobon M, Barrett AS, Petricoin EF, O'Shaughnessy JA., Free PMC Article | 03/6/2024 |
| HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer. | HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer.
Li Q, Su X, Qing L, Xu W, Yang Y, You C, Wang J, Dong Z. | 03/4/2024 |
| ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features. | ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
Forster-Sack M, Zoche M, Pestalozzi B, Witzel I, Schwarz EI, Herzig JJ, Fansa H, Tausch C, Ross J, Moch H, Varga Z., Free PMC Article | 02/27/2024 |